HLS Therapeutics Inc. HLS.TO

Set alert

Price alert · HLS.TO

All alert types
4.47 CAD -0.04 -0.89%

As of Nov 2, 3:59 PM ET

4.41 Day range 4.62
0.001 52-week range 5.61
YTD
-7.26%
1 year
-19.89%
Open
4.49
Prev close
4.51
Mkt cap
138.28M
Vol
10.90K
Avg vol
74.02K
EPS
-0.37
P/E
0.00
Div yield
0.00%
More statistics
Low
4.41
High
4.62
Forward P/E
-7.50
Beta
1.07
Short ratio
0.10
Inst. own
65.14%
Dividend
0.00
Ex-div date
Apr 26, 2023
50-d avg
3.54
200-d avg
3.70
1y target
6.09

2Y chart

Chart tools
Interval

Signals (80)
NameDateAgo
RSI: OverboughtOct 27, 20266 days ago
SMA: BullishOct 23, 20261 week ago
MACD: Buy SignalOct 23, 20261 week ago
MACD: Sell SignalOct 16, 20262 weeks ago
SMA: BullishOct 5, 20264 weeks ago
SMA: BearishOct 1, 20261 month ago
SMA: BullishSep 25, 20261 month ago
SMA: BearishSep 18, 20261 month ago
SMA: BullishSep 14, 20261 month ago
MACD: Buy SignalSep 8, 20261 month ago
MACD: Sell SignalSep 2, 20262 months ago
MACD: Buy SignalSep 1, 20262 months ago
RSI: OversoldAug 11, 20262 months ago
MACD: Sell SignalAug 6, 20262 months ago
MACD: Buy SignalJul 27, 20263 months ago
MACD: Sell SignalJul 23, 20263 months ago
MACD: Buy SignalJul 22, 20263 months ago
MACD: Sell SignalJul 14, 20263 months ago
MACD: Buy SignalJul 7, 20263 months ago
MACD: Sell SignalJul 2, 20264 months ago

Newest 20 of 80.

Key statistics

Market cap
119.22M
Enterprise value
173.16M
Trailing P/E
0.00
Forward P/E
-7.50
PEG ratio
0.00
Price / sales
2.09
Price / book
1.50
EPS (TTM)
-0.99
Beta
1.07
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-38.70%
Revenue (TTM)
56.94M
Revenue growth
-12.20%
Free cash flow
27.20M
Total cash
17.54M
Total debt
68.62M
Return on equity
-24.33%
Shares outstanding
31.79M
Short % of float
0.00%
50-day average
3.54
200-day average
3.70

Analyst view

Consensus: none

Price target (mean) 6.09 +36.2% upside
Target (low)
3.61
Target (mean)
6.09
Target (high)
9.81
Ratings (0m) 5 2 buy · 3 hold · 0 sell
  • Strong buy0
  • Buy2
  • Hold3
  • Sell0
  • Strong sell0

Next earnings

Consensus EPS estimate -0.09.

Earnings history

Upgrades / downgrades

HLS.TO analyst upgrades and downgrades
DateFirmActionFromTo
Mar 18, 2024Raymond JamesmainMarket PerformMarket Perform
Aug 6, 2021Raymond JamesdownOutperformMarket Perform

About HLS Therapeutics Inc.

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
Canada

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on HLS.TO — it syncs with the Stock Master app.

Institution ownership

HLS.TO institution ownership
Holder% heldSharesValueReported
Canoe Financial LP 1.54%499,0011.87MMar 30, 2023

Fund ownership

HLS.TO fund ownership
Holder% heldSharesValueReported
DFA Investment Dimensions-Canadian Small Company Series0.06%20,10475.39KJul 30, 2024
Highland Fds II-Highland Global Allocation Fd0.03%10,44539.17KSep 29, 2024
DFA Investment Dimensions-DFA Va International Small0.01%2,90310.89KJul 30, 2024
DFA Investment Dimensions-World Ex U.S. Core Equity Port0.01%2,0007.50KJul 30, 2024
Lincoln VIP Tr-Dimensional International Core Equity Fd0.01%2,3178.69KSep 29, 2024
John Hancock Fds II-International Small Company Fund0.01%2,6009.75KOct 30, 2024